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Abstract High-sensitivity titration calorimetry is used to
measure changes in enthalpy, heat capacity and protonation for
the binding of captopril to the angiotensin I-converting enzyme
(ACE; EC 3.4.15.1). The affinity of ACE to captopril is high and
changes slightly with the pH, because the number of protons
linked to binding is low. The determination of the enthalpy
change at different pH values suggests that the protonated group
in the captopril-ACE complex exhibits a heat protonation of
approximately 330 kJ/mol. This value agrees with the protona-
tion of an imidazole group. The residues which may become
protonated in the complex could be two histidines existing in two
active sites, which are joined to the amino acids coordinated to
Zn2+. Calorimetric measurements indicate that captopril binds to
two sites in the monomer of ACE, this binding being
enthalpically unfavorable and being dominated by a large
positive entropy change. Thus, binding is favored by both
electrostatic and hydrophobic interactions. The temperature
dependence of the free energy of binding vG‡ is weak because
of the enthalpy-entropy compensation caused by a large heat
capacity change, vCp =34.3 þ 0.1 kJ/K/mol of monomeric
ACE. The strong favorable binding entropy and the negative
vCp indicate both a large contribution to binding due to
hydrophobic effects, which seem to originate from dehydration
of the ligand-protein interface, and slight conformational changes
in the vicinity of the active sites.
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1. Introduction
Angiotensin I-converting enzyme (ACE; EC 3.4.15.1) plays
an important role in blood pressure regulation. It is a dipep-
tidyl carboxypeptidase which converts angiotensin I into the
potent vasopressor peptide angiotensin II and inactivates the
vasodepressor peptide bradykinin [1]. ACE is an unusual zinc-
metallopeptidase in that it is activated by chloride and lacks a
narrow in vitro substrate speci¢city [2].
Inhibition of ACE is a widely used approach in the treat-
ment of hypertension. The ¢rst available competitive inhibi-
tors of ACE were the naturally occurring peptides in snake
venom. Clinical studies using the nonapeptide teprotide, the
most e⁄cient of these snake venom peptides in vivo, demon-
strated the potential of ACE inhibitors as antihypertensive
drugs. A lot of highly potent inhibitors of ACE which can
be taken orally have subsequently been developed during the
past two decades [3,4].
The molecular cloning and sequencing of the complemen-
tary DNA for human ACE revealed that ACE (somatic iso-
zyme of ACE) is a glycoprotein that consists of a single poly-
peptide chain containing two homologous domains called the
N and C domains, each bearing a potential catalytic site [5^7].
ACE is found as a membrane-bound enzyme via its hydro-
phobic C-terminal segment and also as a circulating molecule
in plasma [8]. The latter seems to be secreted from the former
by the action of an unknown protease and shows enzymatic
activity [9] indicating that the C-terminal region of the native
enzyme is not needed for the catalytic activity [10^12]. In
vitro, a soluble active form of it can be obtained from the
lung enzyme by limited proteolytic cleavage [11,13].
The three-dimensional structure of ACE is still unknown,
but the crystal structures of other zinc metalloproteases have
been elucidated. Although carboxypeptidase A and ACE are
quite distinct structurally, both enzymes are zinc-containing
exopeptidases with some similar properties. These facts sug-
gested that the nature of the catalytic process, and therefore
of the active sites, was similar in both cases. Thus, taking into
account the analogy among the catalytic sites of carboxypep-
tidase A, thermolysin and ACE, potent competitive inhibitors
of ACE have been designed [4]. The ¢rst of these, captopril
(D-[3-mercapto-2-methylpropanoyl]-L-proline), was designed
with the help of a theoretical model of the active site of
ACE, which was based on its presumed similarity to the
known active site of carboxypeptidase and also with reference
to the C-terminal sequences of the venom peptides which
complete with substrates [5^17].
In order to determine and quantify the forces driving asso-
ciation of captopril and ACE, we have studied the energetic of
binding of the inhibitor to the enzyme as both a function of
temperature and pH using isothermal titration calorimetry
(ITC). The characterization of the binding was carried out
over the pH range 6^8 in a series of bu¡er solutions with
di¡erent heats of ionization, in order to have an estimate of
the high-a⁄nity equilibrium binding constant for the ACE/
captopril interaction [18]. Those experiments allow us also
to calculate the number of protons linked to ligand binding.
In the present study, the calorimetric titration of captopril
to ACE was examined at four temperatures within the range
16^30‡C. At pH 7, the enthalpy changes are positive within
the range of temperature studied and decrease linearly with
the temperature, given a large negative value of vCp. The
formation of complex between captopril and the enzyme is
entropically driven. The results obtained are discussed in
terms of the possible interaction between the inhibitor and
the enzyme.
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2. Materials and methods
2.1. Chemicals
Cacodylate, MES, Aces, Tris, HEPES and FAPGG were purchased
from Sigma. ZnCl2 was from Merck. Sephacryl S-300 HR was pur-
chased from Pharmacia. Centripred 30 concentrators were from Ami-
con. All other chemicals were reagent grade of the highest purity
available.
2.2. Enzyme
ACE was prepared from bovine lung by the method described by
Garc|Ła-Fuentes et al. [13]. A soluble angiotensin I-converting enzyme
form was obtained from puri¢ed membrane-bound enzyme, using
trypsin treatment and separated by Sephacryl S-300 HR chromatog-
raphy [13]. The trypsin solubilizes the protein by deletion of a
fragment of 10 kDa, approximately. Thus, the molecular mass of
the monomer was taken as 160 kDa [13]. The enzyme showed a
single-band pattern in polyacrylamide gel electrophoresis in the pres-
ence of sodium dodecyl sulfate and showed no detectable trypsin
activity.
Solutions of ACE were concentrated on Centriprep 30 concentra-
tors and prepared by dialysis of the enzyme against several changes of
0.3 M NaCl, 50 WM ZnCl2, 50 mM bu¡er A (cacodylate, MES and
Aces at pH 6; cacodylate and HEPES at pH 7; HEPES and Tris at
pH 8), and 4‡C. Protein concentration was determined from absorb-
ance measurements at 280 nm using the bovine-lung-enzyme absorb-
ance coe⁄cient 2.1U105 M/cm [19]. The activity of lung ACE was
determined by the spectrophotometric method of Holmquist et al. [20]
at 25‡C, with 2-furanacryloyl-L-phenylalanylglycylglycine (FAPGG)
as substrate. Reaction mixtures contained 100 WM FAPGG in 50
mM bu¡er A, 0.3 M NaCl, 10 WM ZnCl2 and 5^12 nM ACE at
pH 7.5. Absorbance measurements at 334 nm were carried out in a
Beckman DU-7400 spectrophotometer with the cells maintained at
25‡C. One unit of activity is de¢ned as the amount of ACE that
produces a vA334/min of 1.0. The speci¢c activity of puri¢ed enzyme
was 24^26 min/mg.
All solutions were degassed and clari¢ed through a 0.45-Wm Milli-
pore ¢lter immediately before use.
2.3. Calorimetric experiments
ITC experiments were performed in a calorimeter built in our labo-
ratory, interfaced with a personal computer using an A/D converter
board (Data Translation DT-2805) for automatic instrument control
and data collection. The characteristics of this instrument are similar
to other calorimeters, such as those described by McKinnon et al. [21]
and Freire et al. [22]. A circulating water bath was used to help
stabilize the experimental temperature. The titration experiments
were carried out as described elsewhere [23,24]. The instrument was
calibrated by (i) measuring the area under a test electrical heat pulse
and comparing it with the heat input and (ii) measuring the heat of a
standard chemical reaction. For the latter, the heat of protonation of
glycine by HCl was measured [25]. The two calibration methods were
in excellent agreement. Test runs were repeated periodically to ensure
continued accuracy in the performance of the calorimeter. The calo-
rimeter includes an electrical compensation circuit for a rapid return
to base-line level after each injection. To measure the dilution heat of
captopril in the absence of ACE, control experiments were performed
in which the protein solution in the sample cell was replaced by the
dialysate bu¡er. The dilution heats in the presence of the ACE-cap-
topril complex were estimated from the enthalpies for injections of
captopril measured after all ACE binding sites had been saturated.
The dilution heats in the presence of complex obtained from the last
peaks were used to correct the binding enthalpy for the heat of dilu-
tion.
The concentration of the solutions employed in the calorimetric
experiments were in the range 20^50 WM of ACE. The thermal e¡ect
of the protein dilution was negligible in all cases. The activity of the
enzyme was routinely checked just before and after the calorimetric
experiment. The ACE-captopril complex from calorimetric experiment
showed less than 1% activity.
Similarly, the pH values of the bu¡ers, captopril, and protein so-
lutions were controlled at each temperature before and after the bind-
ing reaction.
2.4. Relationship between protonation and pH dependence of
ligand-binding a⁄nity
The number of protons linked to a ligand-binding reaction of a
macromolecule, nH , can be determined indirectly from the measured
values of the ligand-binding equilibrium constant, K, vs. pH, accord-
ing to the relationship
D log K
D pH
 nH 1
where temperature, pressure, and the thermodynamic activities of all
solution components other than the protons are held constant. Carry-
ing out integration of Eq. 1 between two pH values leads to
log KpH2  log KpH13
Z pH2
pH1
nH dpH 2
This equation indicates that we can determine the ligand binding
equilibrium at a given pH by two independent measurements, repre-
sented by the two terms on the right-hand side of Eq. 2: (i) determi-
nation of the binding equilibrium constant under convenient pH con-
ditions, and (ii) integrated nH vs. pH data.
3. Results and discussion
3.1. FA-Phe-Gly-Gly hydrolysis: bu¡er and pH dependence
The variation of log(vo/[E]) for FAPGG hydrolysis as a
function of pH is shown over the pH range from 6 to 9
(Fig. 1) at di¡erent bu¡er solutions. Throughout this range,
the hydrolysis of substrate follows ¢rst-order kinetics. The
assays were carried out in 0.3 M chloride, which is the optimal
concentration where the initial velocity is maximal. The pH-
rate pro¢le exhibits an optimum centered at pH 7.3 and falls
o¡ when the pH is di¡erent from this value. This pro¢le is
characterized by the ionization of two groups on the free
enzyme. Thus, for the bu¡ers examined and within the pH
range studied, there is no e¡ect of bu¡er concentration in the
rate of FAPGG hydrolysis.
3.2. Stoichiometry and a⁄nity of ACE-captopril binding
Fig. 2 shows a sample data set for the calorimetric titration
of monomeric ACE with captopril in bu¡er HEPES at pH 7
and 16‡C. For the titration of ACE there are 9 consecutive
equivalent 15-Wl injections (spaced at 4-min intervals) of a
captopril solution into the enzyme solution. The positive
sign of the measured heat indicates that the enthalpy change
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Fig. 1. pH dependence of the bovine lung angiotensin I-converting
enzyme catalyzed hydrolysis of 100 WM of FAPGG determined at
25‡C in 0.3 M sodium chloride in either 50 mM HEPES (E), Aces
(b), Tris (R), MES (a) or cacodylate (8) bu¡ers. The solid line de-
scribes a theoretical curve for the pH dependence of a diprotic sys-
tem with apparent pK values of 6.4 and 8.2.
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for each injection was positive and that the process of binding
under these conditions was endothermic. Control experiments
were made as described in Section 2 and represent the dilution
heat of captopril and the heat e¡ects from non-chemical re-
action sources, which have not been compensated with dual
injection into the sample and reference cells. The fact that no
signals are observed from the sixth injection to the end of the
titration in Fig. 2A shows that saturation has been reached in
the ¢rst ¢ve injections. Fig. 2B shows how the total heat
increases linearly with the ligand concentration until satura-
tion is reached at a stoichiometry of 2 mol of captopril per
mol of ACE monomeric. The heat absorbed in the ¢rst ¢ve
injections of captopril is seen to be identical, indicative of
tight binding. This result agrees with previous works, which
have demonstrated that captopril binding to ACE is tight [26^
28]. At pH 7 the intrinsic binding constant estimated by using
a two site independent and non-interacting model is s 108
M31, which is the upper limit of detectability for the instru-
ment. Identical experiments to that described above were car-
ried out at pH 6 and 8 in di¡erent bu¡er solutions. The en-
thalpy changes obtained are given in Table 1. As we will
describe below, these experiments allow the estimation of
the number of protons linked to the complex formation.
These values are too small (Table 1) to decrease the a⁄nity
of captopril to monomeric ACE with a change of pH, and
thus it is impossible to calculate the ¢rst term on the right-
hand side of Eq. 2. The second term can be calculated using
the values given in Table 1. If the same number of protons
taken up by each site in the monomer of ACE is assumed, the
result indicates that the equilibrium constant changes less than
an order of magnitude with a variation of pH between 6 and
8. Even if the number of protons taken up by each site were
di¡erent, the variation in the equilibrium constant would also
be small. For this reason, in other bu¡er solutions and pH
values, no attempt has been made to obtain equilibrium bind-
ing constant from the calorimetric titration data, since the
high a⁄nity of ACE-captopril association precludes the deter-
mination of a⁄nity by calorimetric titration as described by
Wiseman et al. [29]. Experiments were designed to facilitate
the accurate measurement of the enthalpy and stoichiometry
of ACE-captopril binding. The results obtained prove that
captopril, as lisinopril [30], binds to the two potential active
sites identi¢ed in the sequence of somatic ACE [7], with an
association constant higher than 108 M31, which changes little
over a pH range of 6^8.
3.3. Measurements of protons linked to ligand binding
As has been said above, a series of titration calorimetry
binding measurements were made for captopril to ACE as a
function of pH in the presence of two or three di¡erent bu¡er
solutions, which are given in Table 1.
If the binding reaction involves a change in protonation,
the observed heats by titration calorimetry are apparent en-
thalpies, which include contributions from the binding enthal-
py and ionization enthalpy of the bu¡er in proportion to
uptake or release of ligand-linked protons. The measured
vHT is the sum of the reaction binding enthalpy, vHb, which
is independent of the bu¡er, and a term proportional to the
change of ionization of the bu¡er
vHT  vHb  nHvHion 3
where nH is the number of protons taken up by the complex
during the binding reaction and vHion the ionization heat of
the bu¡er. The binding enthalpy and number of linked pro-
tons were calculated from vHT obtained for each bu¡er at
constant pH by Eq. 3. These data are also listed in Table 1.
As the binding enthalpy change, vHb, is positive, vS‡ must
also be positive and the binding process is entropy driven over
the pH range of 6^8. Therefore, the interaction of this drug
with ACE is strongly endothermic in nature. This behavior is
similar to that showed by the interaction lisinopril/ACE [30].
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Fig. 2. Calorimetry titration of the binding of captopril to the bo-
vine lung angiotensin I-converting enzyme at pH 7 and 16‡C. A:
The programmed sequence consisted of 9 injections of 15 Wl each of
1.2 mM captopril stock solution. The captopril and bu¡er solution
were injected into a sample cell containing 2.9 ml of 15.4 WM
monomeric ACE and a reference cell containing 2.9 ml of bu¡er
(0.3 M NaCl, 50 WM ZnCl2, 50 mM HEPES). The data shown in
A are the di¡erences between the sample and reference cells, and in
B the cumulative enthalpy, vHc, as a function of molar ratio of
captopril to ACE monomer.
Table 1
Captopril binding heats of ACE in di¡erent bu¡ers and at di¡erent pH conditions to yield the binding enthalpies and linked protons
pH Bu¡er vHion (kJ/mol) vHT (kJ/mol) vHb (kJ/mol) Linked protons (per mol ACE)
6 Cacodylate 31.25 80.17 81.10 0.54
6 Cacodylate 31.25 81.03 81.10 0.54
6 MES 15.38 88.30 81.10 0.54
6 Aces 31.5 99.00 81.10 0.54
7 Cacodylate 31.25 85.00 85.60 0.48
7 HEPES 20.57 95.56 85.60 0.48
8 Tris 48.09 94.82 98.94 30.08
8 HEPES 20.57 97.18 98.94 30.08
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As can be observed in Table 1, the protons are taken up at
pH 6 and 7 and are practically zero at pH 8. The protonation
changes for captopril-ACE binding can be viewed as arising
from a shift in the pK of one or more groups on complex
formation. Alterations in the protonation state of certain res-
idues in the vicinity of the captopril binding site may explain
the variation of number of protons at three pHs examined.
Notice in Eq. 3 that while the binding enthalpy was corrected
for the enthalpy of bu¡er ionization, vHb retains contribu-
tions from the ionization enthalpies of groups on the protein,
the ligand or both. Thus, vHb can be the sum of a term that
does not depend on the ionization of groups, and corresponds
to the intrinsic binding enthalpy, and a term proportional to
the change of ionization of ACE and/or captopril. At this
point, it is interesting to consider that probably there are
His residues in both active sites of N and C domains. Soubrier
et al. [31] indicated that both His-360 and -388 in domain N,
and both His-958 and -986 in domain C, are joined to the
amino acid residues coordinated with Zn2 (His-361, His-365,
Glu-389, His-959, His-963 and Glu-987). Considering the pos-
sible pK value of this residue in the protein and its ionization
enthalpy change, a shift in its pK value can explain the uptake
of protons obtained at the pH range studied. Since the num-
ber of protons taken is practically zero at pH 8, the intrinsic
binding enthalpy would be approximately 98.94 kJ/mol ACE.
There are several reasons that can explain these changes in pK
values. For instance, a variation in the micropolarity of the
environment surrounding the side chains of certain active site
residues as a result of captopril binding is a possibility. Alter-
natively, a protonated form could be stabilized by forming a
hydrogen bond with a neighboring group. The contribution of
protonation to vHb suggests also that groups with low ion-
ization heat like Glu or Asp practically do not take up pro-
tons upon binding. Since the vHb changes with the pH within
the range studied, a corresponding change in the nH with
temperature given by the following relation [32,33] will take
place
DvHb
DpH
 
T
 32:3RT2 DnH
DT
 
pH
4
3.4. Heat capacity change vCp and temperature dependence of
the thermodynamic parameters
As a function of temperature between 16 and 30‡C, we
analyzed the interaction between captopril and ACE in caco-
dylate bu¡er and pH 7. The reaction heat observed, corrected
by the bu¡er ionization heat (Table 1), vHb, depends linearly
on temperature in the range 16^30‡C. vCp =34.3 þ 0.1 kJ/K/
mol was obtained from the slope of vHb vs. temperature in
Fig. 3. A rather high negative vCp value is normal in binding
studies [24,30,34,35], and is a distinctive feature of site-speci¢c
binding [36^38].
The entropy change was calculated from the vHb obtained
and using the value of vG‡ calculated from the microscopic
binding constants [28]. The vS‡ value is also displayed in
Table 2. The standard state is that of 1 mol/l. The calculation
of thermodynamic functions implies the usual approximation
of setting standard enthalpies equal to the observed ones.
For all temperatures at which measurements have been
made, the binding enthalpy contributes non-favorably to the
free energy of binding. As temperature increases, the binding
enthalpy becomes less endothermic (more favorable). As can
be seen in Fig. 3, the enthalpy change decreases quickly with
temperature due to a large negative heat capacity. The bind-
ing process is accompanied by a large positive entropy change,
which depends also strongly on temperature, while vG‡
changes little with temperature because of the enthalpy-entro-
py compensation. This behavior has been found in many li-
gand-protein interactions [23,24,30,39^41].
The positive enthalpy change and large positive entropy
change of binding upon complex formation can be justi¢ed
by electrostatic and hydrophobic interactions. It is probable
that the captopril-ACE complex has an electrostatic interac-
tion between the zinc ion and the some group from captopril.
Electrostatic interactions correlate well with some postulated
interactions in designed inhibitors on the assumption that
ACE has similar active sites to thermolysin and carboxypep-
tidase A [16,17]. In the spatial structure of these two related
enzymes [42^44], two histidines, one glutamate and one water
molecule coordinate the zinc ion. Although the three-dimen-
sional structure of ACE has not been yet determined, the
sequence is known and corresponding residues of His and
Glu are found in the N and C domains [31]. Monzingo and
Matthews [44] crystallized some inhibitors bound to thermo-
lysin and found that the carboxylate of their phenylalanine is
bound to the Zn2. Moreover, in the active site of carboxy-
peptidase A [45] and thermolysin [44] there is an arginine
which binds the C-terminal carboxylate of the substrate. Sim-
ilar interactions are possible between a sulfhydryl group of
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Fig. 3. Temperature dependence of the thermodynamic parameters
for the binding of captopril bovine lung angiotensin I-converting en-
zyme at pH 7. The bu¡er used was 50 mM cacodylate, 0.3 M
NaCl, and 50 WM ZnCl2. The parameters have been corrected for
e¡ects of bu¡er ionization. The heat capacity change associated
with the binding of captopril to ACE was determined by linear re-
gression analysis as the slope of the plot of vHb vs. temperature.
Values of vG‡(T) have been calculated using the equilibrium con-
stants from Deddis et al. [28] and the van ’t Ho¡ equation. The val-
ues of 3TvS‡(T) are calculated from 3TvS‡(T) =vG‡(T)3vHb(T).
Table 2
Apparent thermodynamic parameters for the binding of captopril to
the monomer of bovine lung angiotensin I-converting enzyme at pH
7
Temperature (‡C) vHb (kJ/mol) vG‡ (kJ/mol) vS‡ (J/K/mol)
30.0 25.20 3115.8 460
24.8 47.69 3113.0 540
19.8 70.84 3108.6 610
16.0 85.60 3107.8 700
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captopril and zinc ion of ACE and between an arginine res-
idue of ACE and the carboxyl terminal of captopril. On the
other hand the heterocyclic ring of the prolyl residue of cap-
topril may bind to a hydrophobic pocket of the enzyme. If
signi¢cant apolar surface area is buried at the interaction
interface, the complex formation is accompanied by negative
heat-capacity changes of the system [45^49]. Murphy and
Freire [50] and Spolar and Record [36] have suggested that
the vCp may be described as a phenomenon in hydration
terms, pointing out that changes in vibrational modes appar-
ently contribute litte to vCp. Similarly, Connelly has shown
that the heat capacity of ligand binding can be approximated
by contributions arising from dehydration of solvent exposed
groups [52^54]. Thus, the enthalpy and heat capacity values
provide an estimation of solvent accessibility changes during
the binding [50,51], the values of which are still unknown
since the spatial structure of ACE has still not been deter-
mined. Murphy’s approach [50] can be applied to the intrinsic
binding thermodynamic parameters, which do not retain the
contribution due to protonation of groups in the complex.
The intrinsic binding enthalpy change has already been deter-
mined (98.94 kJ/mol) at 16‡C and the contribution of proto-
nation of groups to heat capacity change can be corrected
assuming that the His residue is the protonated group. The
results of Murphy’s approach indicate that the surface area
buried on complex formation comprises 67% non-polar sur-
face (approximately 3310 Aî 2) and 33% polar surface (approx-
imately 1650 Aî 2). The amount of non-polar surface involved
appeared too large to be accounted for in ‘rigid body’ asso-
ciation [36]. Hence our results suggest that slight conforma-
tional changes in the vicinity of the active sites were also
coupled to binding. That could justify the accessible surface
area values calculated.
3.5. Nature of the favorable entropy of binding
The positive entropy change can be explained by a strong
hydrophobic e¡ect. vS may be described as [36]
vS‡ =vShydr+vStrans+vSspecific where vShydr is the contribu-
tion by the hydrophobic e¡ect. vStrans accounts for the reduc-
tion in the overall rotational and translational degrees of free-
dom, as well as the immobilization of amino acid side chains
at the complex interface. vSspecific describes system-speci¢c
contributions such as reduction of main chain mobility and
entropic contributions from polar interactions. vShydr can be
estimated from vShydr = 1.35 vCp ln(T/386) where vCp (in
J/mol K) is the measured heat capacity change, T the absolute
temperature and 386 the reference temperature at which the
entropy of transfer of non-polar liquids to water vanishes. For
captopril-ACE complex at 25‡C we obtain vShydr = 1.51 kJ/K/
mol. From vS‡ = 0.54 kJ/K/mol, we calculated that
vStrans+vSspecific =30.97 kJ/K/mol. Because of a lack of struc-
tural information on the captopril-ACE complex, we cannot
provide information about the nature of vStrans and vSspecific
which together oppose binding. However, for a number of
bimolecular association reactions, vStrans has been thought
to contribute 30.21 kJ/K/mol of rotational and translation
entropy [36]. Hence, the remaining entropic loss of 30.76
kJ/K/mol must be contributed by the loss in the conforma-
tional restrictions of captopril and ACE. The latter is a sig-
ni¢cant contribution of the total entropic changes, and its
magnitude is 50% lower than the favorable entropic contribu-
tion due to the hydrophobic e¡ect. Hence, unlike the other
cases of protein-ligand interaction, this binding of captopril to
ACE cannot be taken as the ‘rigid body’ interaction [36]. The
interaction between apolar groups of captopril and ACE re-
quires the dehydration of both the protein and the drug and
there is an entropic gain from the transfer of interfacial water
into the bulk solvent. Assuming that vCp value is due princi-
pally to the hydrophobic e¡ect [34] and that the decrease in
heat capacity per mol of water lost is, on average, 24 J/mol/K
[55], one can calculate that about 175^180 water molecules are
released.
The results of the study presented here can be summarized
as: (i) the a⁄nity of ACE to captopril is high and changes
slightly with the pH. The binding is accompanied by a proton
uptake which can be attributed to an increase in the pK of one
or more groups of the drug and/or enzyme in the complex.
Although the nature of the protonated group remains ambig-
uous, the present results suggest that two histidines existing in
both active sites of N and C domains which are not coordi-
nated to Zn2 may become protonated in the complex. (ii)
Captopril binds to two sites in the somatic ACE monomer.
This binding is entropically driven, indicating a strong contri-
bution from hydrophobic e¡ects due to the release of water
molecules when captopril and ACE associate. (iii) The ob-
served heat capacity change is negative and the binding pro-
cess remains dominated by entropy throughout the physiolog-
ical temperature range. Thus, the thermodynamic parameter
values suggest that the driving force for the binding of capto-
pril to ACE is provided by electrostatic interactions and hy-
drophobic e¡ects. Using published correlations between the
heat capacity change and the burial of non-polar surface
area, we are able to estimate the surface area that is buried
in the captopril-ACE complex. These values suggest that the
binding of captopril to ACE produces slight conformational
changes in the vicinity of the active sites.
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